# Psychedelic drugs in psychiatry: on psilocybin - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1014 - Language: en - Last updated: not specified - Page title: Psychedelic drugs in psychiatry: on psilocybin | WCP 2026 Summary > The current literature suggests that, under controlled and monitored conditions, psilocybin may offer potential benefits in areas such as treatment-resistant d… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1014) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1014 E-PosterPsychopharmacologyReview # Psychedelic drugs in psychiatry: on psilocybin PSYCHEDELIC DRUGS IN PSYCHIATRY: LET’S TALK ABOUT PSILOCYBIN Presenter: Mariana B. Barroso Fonseca Country: Portugal The current literature suggests that, under controlled and monitored conditions, psilocybin may offer potential benefits in areas such as treatment-resistant depression, alcohol use disorder, and pain management in palliative care. The aim is to examine the therapeutic effects of psychedelics, particularly psilocybin, in the treatment of various psychiatric disorders through the current literature. The method is a literature review of publications selected for their relevance to the study objectives. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous mushroom species and has recently been studied for its potential benefits in addictions, particularly alcohol use disorder, and in pain relief in palliative care. In 2021, a randomized controlled phase 2b trial investigating psilocybin-assisted therapy for treatment-resistant depression, in which the Champalimaud Foundation in Lisbon participated, enrolled 233 participants; a single 25 mg dose of psilocybin administered with psychological support produced a significant reduction in depressive symptoms. Changes in neuronal reactivity and emotional components induced by psilocybin therapy in alcohol use disorder were examined; increased activity was observed in the medial and lateral prefrontal cortex and the left caudate nucleus, while decreased activity was found in the insular, motor, temporal, parietal, and occipital cortices and the cerebellum. These changes were associated with improved emotion regulation and reduced craving. In palliative care, case reports suggest that psilocybin may be a safe and effective option for pain relief through mechanisms consistent with current knowledge of nociception and central sensitization; recent studies in major depressive disorder also report clinically significant improvements in depressive symptoms. Psilocybin was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression in 2018 and for major depression in late 2019. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2059) How to cite this study APA 7: Fonseca, M. B. B., et al. (2026, September 23-26). Psychedelic drugs in psychiatry: let’s talk about psilocybin [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2059 Vancouver: Fonseca MBB, et al. Psychedelic drugs in psychiatry: let’s talk about psilocybin [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2059 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1014 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim